Court Reporting
Our reporters understand that the facts you elicit during discovery are essential building blocks for your case. The exact words matter. So we deliver accurate transcripts, bolstered by a quality video recording.
Read More
Legal Graphics
You have a command of the facts and law of your case. Working together, we’ll apply expert design to help bring vision to your case and present it clearly. We know that technology is only a conduit for your story.
Read More
Trial Presentation
DEG brings a unique skill set and arsenal of experience to the trial process. We provide state-of- the-art technology to assist your creation of efficient, persuasive, and powerful presentations.
Read More
Latest News
21Feb
DEG’s support of Finnegan and their client Biogen help win sweeping victory against Mylan over patent dispute regarding best-selling multiple sclerosis drug, Tecfidera
The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) gave a favorable ruling to Biogen who holds a market exclusivity in the United States until 2028 on their ’514...
7Feb
With the assistance of DEG, Sterne Kessler wins favorable ITC ruling for vaping pioneer, JUUL Labs, Inc.
DEG supported Sterne Kessler and their client, vaping giant, JUUL Labs Inc. in Certain Electronic Nicotine Delivery Systems and Components Thereof, investigation number 337-TA-1139, before the U.S. International Trade Commission. The commission partly affirmed Judge...
1Oct
DEG’s clients secure acquittal and new trial for former Platinum executive and co-founder
DEG is proud to have supported the trial teams of Wilson Sonsini Goodrich & Rosati PC and Ford O’Brien in their defense of Mark Nordlicht and David Levy accused of defrauding bondholders of an oil...
21Sep
DEG works alongside Finnegan’s stellar trial team who secures patent protection for Relistor Tablets until March 2031
The U.S. District Court of New Jersey upheld the validity of Bausch Health Companies Inc.’s patent protecting Relistor (methylnaltrexone bromide) tablets and determined Actavis’ infringement of the patent for opioid-induced constipation in patients with chronic...